Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07741565 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT07741565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07741565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2031
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc, oral cancer, scc - squamous cell carcinoma